69 related articles for article (PubMed ID: 30293754)
1. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.
Chen R; Palmer JM; Tsai NC; Thomas SH; Siddiqi T; Popplewell L; Farol L; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1864-8. PubMed ID: 25008328
[TBL] [Abstract][Full Text] [Related]
3. Hodgkin lymphoma: A review and update on recent progress.
Shanbhag S; Ambinder RF
CA Cancer J Clin; 2018 Mar; 68(2):116-132. PubMed ID: 29194581
[TBL] [Abstract][Full Text] [Related]
4. The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.
Klyuchnikov E; Bacher U; Kröger N; Kazantsev I; Zabelina T; Ayuk F; Zander AR
Adv Hematol; 2011; 2011():974658. PubMed ID: 20981158
[TBL] [Abstract][Full Text] [Related]
5. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
Gribben JG; Zahrieh D; Stephans K; Bartlett-Pandite L; Alyea EP; Fisher DC; Freedman AS; Mauch P; Schlossman R; Sequist LV; Soiffer RJ; Marshall B; Neuberg D; Ritz J; Nadler LM
Blood; 2005 Dec; 106(13):4389-96. PubMed ID: 16131571
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.
Reddy N; Savani BN
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1265-72. PubMed ID: 21621630
[TBL] [Abstract][Full Text] [Related]
7. Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics.
Grant M; Cooke L; Williams AC; Bhatia S; Popplewell L; Uman G; Forman S
Support Care Cancer; 2012 Nov; 20(11):2697-704. PubMed ID: 22318502
[TBL] [Abstract][Full Text] [Related]
8. Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort.
Nihtilä J; Salmenniemi U; Itälä-Remes M; Crossland RE; Gallardo D; Bogunia-Kubik K; Łacina P; Bieniaszewska M; Giebel S; Hyvärinen K; Kekäläinen E; Ritari J; Partanen J
Hum Immunol; 2024 Mar; ():110791. PubMed ID: 38553383
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
Shanbhag S; Prasad V
Eur J Cancer; 2018 Nov; 104():252-253. PubMed ID: 30342911
[No Abstract] [Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety.
Dada R; Usman B
Eur J Haematol; 2019 Feb; 102(2):150-156. PubMed ID: 30341987
[TBL] [Abstract][Full Text] [Related]
12. Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma.
Zinzani PL; Santoro A; Chiti A; Lastoria S; Pinto A; Rigacci L; Barosi G; Pennisi M; Corradini P
Leuk Lymphoma; 2019 May; 60(5):1204-1213. PubMed ID: 30322329
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin Infusion Reaction Management: A Case Study.
Comer H; Cardwell K
J Adv Pract Oncol; 2017; 8(6):626-629. PubMed ID: 30310723
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective.
Large S; Hettle R; Balakumaran A; Wu E; Borse RH
J Med Econ; 2018 Nov; ():1-10. PubMed ID: 30303022
[TBL] [Abstract][Full Text] [Related]
15. Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes.
Castagna L; Santoro A; Carlo-Stella C
J Blood Med; 2020; 11():389-403. PubMed ID: 33149713
[TBL] [Abstract][Full Text] [Related]
16. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS
Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675
[TBL] [Abstract][Full Text] [Related]
17. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.
Kallam A; Vose JM
Oncology (Williston Park); 2019 May; 33(5):192-8. PubMed ID: 31095720
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
[TBL] [Abstract][Full Text] [Related]
19. Current treatment paradigms for advanced stage Hodgkin lymphoma.
Longley J; Johnson PWM
Br J Haematol; 2019 Jan; 184(1):60-71. PubMed ID: 30408156
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
